CAMBRIDGE, Mass. (AP) — Aveo Pharmaceuticals Inc. reported a wider fourth-quarter loss Tuesday as it continued to study its experimental cancer drugs tivozanib and ficlatuzumab.

Aveo said it lost $25.2 million, or 58 cents per share, during the fourth quarter. A year earlier it posted a loss of $10.3 million, or 30 cents per share. Revenue from collaborations with companies like Astellas Pharma and Johnson & Johnson fell to $1.1 million from $12 million.

Analysts expected the company to report a loss of 57 cents per share and $5 million in revenue, according to FactSet.

Aveo said its results reflect greater manufacturing costs for tivozanib and ficlatuzumab and one-time costs from strategic, legal, and financial advisers related to its collaboration with Astellas. Astellas is Aveo's partner on tivozanib, the most advanced drug candidate for Aveo. In January the companies said the drug met its goal in a late-stage clinical trial, as patients who took tivozanib had greater progression-free survival than patients who took Nexavar, a drug made by Onyx Pharmaceuticals Inc. and Bayer.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.